Physician profile
Kourtni E Prodan
NPI 1588260574
$871.41
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $428 · 2022: $443.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $339.49 | 2021-2022 | |
| Novo Nordisk INC | $167.82 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.20 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.67 | 2021-2022 | |
| Pfizer INC. | $44.19 | 2021-2022 | |
| Amarin Pharma, INC. | $42.22 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.85 | 2021 | |
| Merck Sharp & Dohme LLC | $26.84 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.11 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.02 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kourtni Prodan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.